Story perspectives

Trump Signs Order to Accelerate Psychedelic Drug Research

4/22/2026

Center

Trump Accelerates Psychedelic Research

U.S. President Donald Trump signed an April 18, 2026 executive order to accelerate research on psychedelic drugs, including Ibogaine, Psilocybin, and MDMA.
The order aims to facilitate clinical trials and improve access for patients with severe mental health conditions.
The U.S. Food and Drug Administration (FDA) plans priority vouchers for psychedelics to speed approvals, while insurance coverage and access remain uncertain because Ibogaine is Schedule I.

Right

Vitiello Credits Technology

On April 15, 2026, U.S. Customs and Border Protection seized over $1.1 million worth of cocaine at Pharr International Bridge, Texas, hidden in a tractor-trailer from Mexico.
Acting CBP Deputy Commissioner Ron Vitiello credited technology and inspections for preventing drug entry.
In March 2026, CBP seized more than 65,000 pounds of drugs, including 613 pounds of fentanyl, while officials attribute the results to "America First policies" under U.S. President Donald Trump.

1 of 2

Trump Accelerates Psychedelic Research

U.S. President Donald Trump signed an April 18, 2026 executive order to accelerate research on psychedelic drugs, including Ibogaine, Psilocybin, and MDMA.
The order aims to facilitate clinical trials and improve access for patients with severe mental health conditions.
The U.S. Food and Drug Administration (FDA) plans priority vouchers for psychedelics to speed approvals, while insurance coverage and access remain uncertain because Ibogaine is Schedule I.

1 / 2